ADI-001 Highly Effective, Safe for Heavily Pretreated NHL in Preliminary Phase 1 Data
ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy.
Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD
The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.
Axi-Cel Superior to SoC in Second-Line Large B-Cell Lymphoma Treatment
Patients treated with the CAR T-cell therapy had an over 4-fold increase in event-free survival.
Gene Edited Cell Therapy Improves Fetal Hemoglobin Expression in Patients With Sickle Cell Disease
All evaluable treated participants experienced a reduction in vaso-occlusive events after treatment with ARU-1801.
Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Improving Personalized Cell Therapies for Solid Tumors
Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.
Gene Therapy for Diabetic Macular Edema Shows Mixed Efficacy, Safety
Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.
Identifying Future Patients for Tmod Cell Therapy in BASECAMP-1: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
Advantages of T-Cell Immunotherapy Over CAR T-Cells
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.
CRISPR/Cas9-Edited CAR and NK Cell Therapies Show Preclinical Efficacy
CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.
Gene Therapy Optogenetics Combination Efficacious in Retinitis Pigmentosa: José-Alain Sahel, MD
The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.
RGX-314 Gene Therapy Efficacious in Wet AMD: Robert L. Avery, MD
The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.
Assessing Tab-Cel for EBV+ Post-Transplant Lymphoproliferative Disease
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed data from the ALLELE study to be presented at ASH 2021.
OpRegen Shows Durable Efficacy in Dry AMD Geographic Atrophy
The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.
CYNK-101 Demonstrates Anti-Tumor Activity in HNSCC Cells
The NK cell therapy is also being evaluated in a phase 1 study for acute myeloid leukemia.
Dendritic Cell Vaccine Boosts Survival in Glioblastoma
Overall survival was 72% at 12 months but dropped to 54% at 14.6 months.
TIL Therapy LN-145 Elicits Responses in Pretreated mNSCLC
A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.
CAR Macrophages Well-Tolerated, May Reprogram Tumor Microenvironments
The first in-human study of CAR macrophages has dosed 2 participants so far.
Tmod CAR T-Cell Therapy Offers Precise Targeting of Solid Tumors
The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.
CAR T-Cell Therapy Plus Amplifying Vaccine Shows Initial Safety, Efficacy in Solid Tumors
Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.
TCR T-Cell Therapy Shows Efficacy Across Solid Tumor Types
Data from the IMA203 trial were presented at the SITC 2021 annual meeting.
Natural Killer Cell Therapy Well Tolerated in Solid Tumors
Thorsten Graef, MD, PhD, chief medical officer, Acepodia, discussed data on ACE1702 presented at ESMO 2021.
Cilta-Cel Shows Durability in Relapsed/Refractory Multiple Myeloma
Overall response rate was 95%, including 75% of patients who achieved a complete response (CR) or better, with a median follow-up of 5.8 months at data cutoff.
Updated KarMMA Data of Ide-Cel in Multiple Myeloma: Larry D. Anderson Jr, MD, PhD
The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.
Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1
The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.
Emerging Data in Diffuse Large B-Cell Lymphoma
Experts discussed data from trials in lymphoma presented at ASCO 2021.
Using A Modular Approach to Develop Oncolytic Cell Therapies
The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.
Gene Therapies for Hemophilia Have Positive Real-World Impact, Studies Show
Presentations at ISTH 2021 revealed attributes most important to patients when considering gene therapies and where further research is needed.
Hemophilia Gene Therapy Registry Launched to Monitor Long-Term Outcomes
The World Federation of Hemophilia’s registry will include long-term safety and efficacy data in people with hemophilia treated with gene therapies.
Fidanacogene Elaparvovec Well-Tolerated in Hemophilia B
No concerning effects to liver health were observed in the phase 1/2a study.
